Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Stomach Neoplasms 1Pancreatic Neoplasms 1Nephrotic Syndrome 1Neoplasm Metastasis 1Kidney Diseases 1Hepatitis B 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Esophageal Neoplasms 1Colorectal Adenocarcinoma 1Cholangiocarcinoma 1BRAF V600 Colorectal Cancer 1Arthritis, Rheumatoid 1Amyloidosis 1Adenomatous Polyposis Coli 1

Interventions

Oxaliplatin 6Irinotecan 5Fluorouracil 5Drug Therapy 4Bevacizumab 4Magnetic Resonance Spectroscopy 3Leucovorin 3Capecitabine 35,10-methylenetetrahydrofolic acid 3pembrolizumab 2Ocoxin 2Levoleucovorin 2Folfox protocol 2Exercise Test 2Cyclophosphamide 2Cetuximab 2trifluridine tipiracil drug combination 1sintilimab 1repotrectinib 1pralsetinib 1penpulimab 1napabucasin 1lutetium Lu 177 dotatate 1huachansu 1guadecitabine 1golotimod 1encorafenib 1copper dotatate CU-64 1alectinib 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Diseases × Pharmaceutical Preparations × Gastrointestinal × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡